Results 231 to 240 of about 15,600,832 (357)

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang   +12 more
wiley   +1 more source

Comparison of the Effects of Dexmedetomidine and Labetalol on Controlled Hypotension in Maxillofacial Surgery

open access: diamond, 2020
Ali Akbar Alizadeh   +5 more
openalex   +1 more source

Clinical, Genetic, and Imaging Characteristics of SCA27B: Insights from a Large Dutch Cohort

open access: yesMovement Disorders, EarlyView.
Abstract Background Deep intronic GAA repeat expansions in intron 1 of the FGF14 gene were identified in 2023 as cause of late‐onset cerebellar ataxia. Since then, GAA‐FGF14‐related ataxia (SCA27B) has emerged as one of the most common genetic causes of late‐onset cerebellar ataxia.
Teije H. van Prooije   +26 more
wiley   +1 more source

Impact of different doses of esketamine on the incidence of hypotension in propofol-based sedation for colonoscopy: a randomized controlled trial

open access: gold
Mengyue Fu   +10 more
openalex   +1 more source

Validation of the French Translation of the Movement Disorder Society Non‐Motor Symptoms Scale (MDS‐NMS) in Parkinson's Disease

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Clément Desjardins   +283 more
wiley   +1 more source

Types of Pain in Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background Pain affects up to 87% of people with multiple system atrophy (MSA), but it remains unclear which types of pain contribute most to the overall burden. Objective To estimate the frequency of different types of pain in MSA individuals.
Nicole Campese   +19 more
wiley   +1 more source

Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis

open access: yesMuscle &Nerve, EarlyView.
Pretreatment with an agonist of Kv7 potassium channels (XEN1101) protects the soleus muscle from a loss of force during a 2 mM K+ challenge, in a mouse model of hypokalemic periodic paralysis. ABSTRACT Introduction/Aims Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP).
Viktor Chanchykov   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy